Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 39, 2020 - Issue 6
167
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Nasolacrimal duct obstruction secondary to lacrimal sac involvement by sebaceous carcinoma

, , , &
Pages 433-436 | Received 01 Sep 2019, Accepted 25 Nov 2019, Published online: 06 Dec 2019

References

  • Muqit MM, Foot B, Walters SJ, Mudhar HS, Roberts F, Rennie IG. Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 2013;97:47–51. doi:10.1136/bjophthalmol-2012-302443.
  • Kaliki S, Gupta A, Ali MH, Ayyar A, Naik MN. Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification. Int Ophthalmol. 2016;36:681–690. doi:10.1007/s10792-016-0187-6.
  • Takahashi Y, Takahashi E, Nakakura S, Kitaguchi Y, Mupas-Uy J, Kakizaki H. Risk factors for local recurrence or metastasis of eyelid sebaceous gland carcinoma after wide excision with paraffin section control. Am J Ophthalmol. 2016;171:67–74. doi:10.1016/j.ajo.2016.08.028.
  • Vahdani K, Coupland SE, Ashdown ME, Garrott H, Ford R. Lacrimal sac sebaceous carcinoma. Ophthalmic Plast Reconstr Surg. 2019. doi:10.1097/IOP.0000000000001386.
  • Rath S, Honavar SG, Reddy VA, Naik MN, Vemuganti GK, Murthy R. Sebaceous carcinoma of the eyelid metastasizing to the lacrimal sac after 5 years. Orbit. 2009;28:309–312. doi:10.3109/01676830903071182.
  • Khan JA, Grove AS Jr., Joseph MP, Goodman M. Sebaceous carcinoma. Diuretic use, lacrimal system spread, and surgical margins. Ophthalmic Plast Reconstr Surg. 1989;5:227–234. doi:10.1097/00002341-198912000-00001.
  • Leibovitch I, Selva D, Huilgol S, Davis G, Dodd T, James CL. Intraepithelial sebaceous carcinoma of the eyelid misdiagnosed as Bowen’s disease. J Cutan Pathol. 2006;33:303–308. doi:10.1111/cup.2006.33.issue-4.
  • El-Sawy T, Frank SJ, Hanna E, Sniegowski M, Lai SY, Nasser QJ, et al. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthalmic Plast Reconstr Surg. 2013;29:454–457. doi:10.1097/IOP.0b013e31829f3a73.
  • Valenzuela AA, McNab AA, Selva D, O’Donnell BA, Whitehead KJ, Sullivan TJ. Clinical features and management of tumors affecting the lacrimal drainage apparatus. Ophthalmic Plast Reconstr Surg. 2006;22:96–101. doi:10.1097/01.iop.0000198457.71173.7b.
  • Valenzuela AA, Selva D, McNab AA, Simon GB, Sullivan TJ. En bloc excision in malignant tumors of the lacrimal drainage apparatus. Ophthalmic Plast Reconstr Surg. 2006;22:356–360. doi:10.1097/01.iop.0000235819.06507.b1.
  • Curragh DS, Psaltis AJ, Tan NC, Selva D. Prelacrimal approach for nasolacrimal duct excision in the management of lacrimal system tumours. Orbit. 2019;38:308–312.
  • Curragh DS, James C, Selva D. Swinging inferior turbinate approach to the nasolacrimal duct. Orbit. 2019;1–6. doi:10.1080/01676830.2019.1595007.
  • Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94:1316–1321. doi:10.1136/bjo.2009.176099.
  • Shields CL, Naseripour M, Shields JA, Eagle RC Jr. Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology. 2002;109:2129–2133. doi:10.1016/S0161-6420(02)01239-3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.